Shanghai Innogen Pharmaceutical Technology Co., Ltd. is a science-driven biotechnology company dedicated to the research and development of innovative and affordable medicines for diabetes and other metabolic disease patients. Innogen’s pipeline in metabolic disease, including Type 1 & 2 diabetes, obesity and NASH, is independently developed and has global market rights.
Supaglutide, the company’s first pipeline product, Efsubaglutide Alfa (previously named as Supaglutide, with trade name: DiabegoneTM ), was approved by the NMPA in January, 2025. It is the first humanized long-acting GLP-1 drug that originated from China, which will benefit more diabetes patients. Other indications for Efsubaglutide Alfa such as obesity and MASH are also under development to address the large unmet therapeutic needs in these disease areas.
Supaglutide, the company’s first pipeline product, Efsubaglutide Alfa (previously named as Supaglutide, with trade name: DiabegoneTM ), was approved by the NMPA in January, 2025. It is the first humanized long-acting GLP-1 drug that originated from China, which will benefit more diabetes patients. Other indications for Efsubaglutide Alfa such as obesity and MASH are also under development to address the large unmet therapeutic needs in these disease areas.
Location: China, Shanghai
Employees: 11-50
Investors 3
| Date | Name | Website |
| 18.05.2025 | Centurium ... | centurium.... |
| - | HONGTAI Ap... | apluscap.c... |
| 02.11.2025 | Cowin Capi... | cowincapit... |
Mentions in press and media 2
| Date | Title | Description |
| 04.08.2026 | Innogen Pharmaceuticals Receives PIC/S GMP Certificatation, Accelerating Global Expansion of Efsubaglutide Alfa | SHANGHAI, Aug. 4, 2026 /PRNewswire/ -- Innogen Pharmaceuticals (HK.2591), a biopharmaceutical company dedicated to innovative drug discovery and industrialization in metabolic diseases, today announced that its Efsubaglutide alfa manufactur... |
| 29.05.2026 | Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA Scientific Sessions | SHANGHAI, May 29, 2026 /PRNewswire/ -- Innogen (HKEX: 2591), a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for metabolic diseases, today announced that new clinical data fr... |